

**S5 Table.** Demographic characteristics of the patients at baseline (the separate cohort)

	Total (n=182)	Short PFS (< 3 m) (n=68)	Long PFS (≥ 3 m) (n=114)	p-value <sup>a)</sup>
Age (yr), median (IQR)	63 (55-70)	63 (52-69)	63 (56-71)	0.261
Sex				0.365
Male	153 (84.1)	55 (80.9)	98 (86.0)	
Female	29 (15.9)	13 (19.1)	16 (14.0)	
Etiology of HCC				0.848 <sup>b)</sup>
Hepatitis B	105 (67.3)	37 (67.3)	68 (67.3)	
Hepatitis C	12 (7.7)	5 (9.1)	7 (6.9)	
Alcohol	21 (13.5)	8 (14.6)	13 (12.9)	
Others	18 (11.5)	5 (9.1)	13 (12.9)	
Cirrhosis				0.551
Yes	146 (80.2)	53 (77.9)	93 (81.6)	
No	36 (19.8)	15 (22.1)	21 (18.4)	
AFP				0.001
< 400 ng/mL	95 (60.9)	24 (43.6)	71 (70.3)	
≥ 400 ng/mL	61 (39.1)	31 (56.4)	30 (29.7)	
ECOG performance status				< 0.001
0	78 (42.9)	15 (22.1)	63 (55.3)	
1	100 (54.9)	50 (73.5)	50 (43.8)	
2	4 (2.2)	3 (4.4)	1 (0.9)	
Portal vein tumor thrombosis				0.013
No	122 (61.5)	34 (50.0)	78 (68.4)	
Yes	70 (38.5)	34 (50.0)	36 (31.6)	
Extrahepatic spread				0.055
No	67 (36.8)	19 (27.9)	48 (42.1)	
Yes	115 (63.2)	49 (72.1)	66 (57.9)	
Prior local treatment				0.037
No	53 (29.1)	26 (38.2)	27 (23.7)	
Yes	129 (70.9)	42 (61.8)	87 (76.3)	
Child-Pugh classification (n=179)				0.001
A5	99 (55.3)	26 (38.8)	73 (65.2)	
A6	47 (26.3)	21 (31.3)	26 (23.2)	
B7	20 (11.2)	10 (14.9)	10 (8.9)	
B8-9	13 (7.3)	10 (14.9)	3 (2.7)	
ALBI grade (n=179)				0.261
1	92 (50.5)	30 (44.1)	62 (54.4)	
2	83 (45.6)	34 (50.0)	49 (43.0)	
3	4 (5.9)	4 (5.9)	3 (2.6)	
BCLC stage (n=181)				< 0.001
B	30 (16.6)	3 (4.4)	27 (23.9)	
C	151 (83.4)	65 (95.6)	86 (76.1)	

Values are presented as number (%) unless otherwise indicated. AFP, α-fetoprotein; ALBI, albumin-bilirubin grade; BCLC, Barcelona Clinical Liver Cancer stage; ECOG, Eastern Cooperative Oncology Group; HCC, hepatocellular carcinoma; IQR, interquartile range; PFS, progression-free survival.

<sup>a)</sup>Fisher's exact test or Pearson's chi-square test, as appropriate, <sup>b)</sup>Fisher's exact test.